Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Autoantibody

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    91 result(s) found for: Autoantibody. Displaying page 2 of 5.
    « Previous 1  2  3  4  5  Next»
    EudraCT Number: 2017-002126-20 Sponsor Protocol Number: PID13341 Start Date*: 2018-08-13
    Sponsor Name:University of Oxford
    Full Title: Interleukin-2 therapy of Autoimmunity in Diabetes: ITAD
    Medical condition: Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    20.1 10027433 - Metabolism and nutrition disorders 10045228 Type I diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2011-005672-42 Sponsor Protocol Number: HGS1006-C1112 Start Date*: 2013-06-11
    Sponsor Name:Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
    Full Title: A Phase 3/4, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Adult Subjects of Black Race With Systemic Lupus...
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004859 10025134 Lupus erythematosus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001269-40 Sponsor Protocol Number: CT-1306 Start Date*: 2008-10-29
    Sponsor Name:Charité University Medicine
    Full Title: Induction of Tolerance with Immunoablation and Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Severe Systemic Lupus Erythematosus (SLE) Refractory to Standard Immunosuppressive Th...
    Medical condition: Patients with systemic lupus erythematosus (SLE) will be under investigation who show high disease activity despite treatment with standard immunosuppressive therapies: high-dose corticosteroids an...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-017329-20 Sponsor Protocol Number: INIT/002 Start Date*: 2010-09-07
    Sponsor Name:Melbourne Health, Royal Melbourne Hospital
    Full Title: A randomised, double-blind, placebo-controlled trial of intranasal insulin (440IU) in children and young adults at risk of type 1 diabetes: INTRANASAL INSULIN TRIAL II
    Medical condition: Type-1-Diabetes
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004366-10 Sponsor Protocol Number: 0642 Start Date*: 2019-05-24
    Sponsor Name:University of Leicester
    Full Title: A Phase 2 Placebo-controlled Double Blinded Study to Assess the Efficacy and Safety of Belimumab in Subjects with Immunoglobulin A Nephropathy (IgAN)
    Medical condition: Immunoglobulin A (IgA) nephropathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10021263 IgA nephropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2025-000106-42 Sponsor Protocol Number: 213560 Start Date*: 2025-04-22
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: Protocol Title: A Multi-Center, Open-Label Study to Evaluate Safety, Efficacy and Pharmacokinetics of Belimumab Plus Standard Therapy in Chinese Paediatric Patients with Active Systemic Lupus Eryth...
    Medical condition: Active Systemic Lupus Erythematosus (SLE)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2011-004570-28 Sponsor Protocol Number: HGS1006-C1121 Start Date*: 2012-09-13
    Sponsor Name:Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Belimumab plus Standard of Care versus Placebo plus Standard of Care in Adult Subjects with Acti...
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) GB (Completed) BE (Completed) ES (Completed) CZ (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-021146-22 Sponsor Protocol Number: 5339 Start Date*: 2012-10-23
    Sponsor Name:The Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Alemtuzumab and rheumatoid arthritis - an immunisation study
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003296-34 Sponsor Protocol Number: OTX116505 Start Date*: 2014-01-29
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Single Blind, Randomised, Placebo Controlled, Repeat Dose, Dose Escalating Study Investigating Safety, Tolerability Pharmacokinetics, Pharmacodynamics and the Beta-Cell Preserving Effect of Oteli...
    Medical condition: NOT1DM is an autoimmune disease. This means that the immune system, the part of the body which usually helps to fight infections, mistakenly attacks cells that produce insulin in the body. Insulin ...
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004870 10003814 Autoimmune disease, not elsewhere classified LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-000225-12 Sponsor Protocol Number: CNTO148DML1001 Start Date*: 2017-08-01
    Sponsor Name:Janssen Biologics BV
    Full Title: A Phase 1b Study to Evaluate SIMPONI® (golimumab) Therapy in Children, Adolescents and Young Adults with Pre-Symptomatic Type 1 Diabetes
    Medical condition: A Phase 1b Study to Evaluate SIMPONI® (golimumab) Therapy in Children, Adolescents and Young Adults with Pre-Symptomatic Type 1 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2021-000471-37 Sponsor Protocol Number: CLOU064A2301 Start Date*: 2021-10-29
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter, randomized, double-blind, placebo-controlled Phase 3 study of remibrutinib (LOU064) to investigate the efficacy, safety and tolerability for 52 weeks in adult chronic spontaneous urt...
    Medical condition: Chronic Spontaneous Urticaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10072757 Chronic spontaneous urticaria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) IT (Completed) ES (Ongoing) BG (Completed)
    Trial results: View results
    EudraCT Number: 2015-003277-15 Sponsor Protocol Number: 8400-211 Start Date*: 2016-09-02
    Sponsor Name:Idera Pharmaceuticals, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of IMO-8400 in Patients with Dermatomyositis
    Medical condition: Dermatomyositis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10040785 - Skin and subcutaneous tissue disorders 10012503 Dermatomyositis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2018-004553-25 Sponsor Protocol Number: CCFZ533X2207 Start Date*: 2019-09-25
    Sponsor Name:Novartis Pharma AG
    Full Title: Investigator- and subject-blinded, randomized, placebo-controlled study to evaluate safety, tolerability, pharmacokinetics and efficacy of CFZ533 in pediatric and young adults with new onset type 1...
    Medical condition: Treatment of subjects with type 1 diabetes mellitus with residual beta cell function (RBCF), with the goal of preserving RBCF
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: BE (Completed) SI (Completed) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002247-28 Sponsor Protocol Number: MOM-M281-004 Start Date*: 2019-02-05
    Sponsor Name:Momenta Pharmaceuticals, Inc.
    Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Adults with ...
    Medical condition: Treatment of MG, with an initial focus on patients with gMG treated with M281 and evaluation of the expected reduction of circulating levels of antibodies by blocking IgG recycling, including the p...
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10028417 Myasthenia gravis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) PL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003814-18 Sponsor Protocol Number: HGS1006-C1115 Start Date*: 2012-05-03
    Sponsor Name:Human Genome Sciences, Inc. (a wholly owned subsidiary of GlaxoSmithKline PLC)
    Full Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) Administered Subcutaneously (SC) to Subjects with Sys...
    Medical condition: Systemic lupus erythematosis (SLE)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004859 10042944 Systemic lupus erythematosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) AT (Completed) CZ (Completed) SE (Completed) BE (Completed) PT (Completed) ES (Completed) DK (Completed) GB (Completed) BG (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2018-004774-97 Sponsor Protocol Number: C-935788-057 Start Date*: 2019-10-23
    Sponsor Name:Rigel Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
    Medical condition: Warm antibody autoimmune hemolytic anemia (wAIHA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BG (Completed) ES (Completed) CZ (Completed) HU (Completed) DK (Completed) DE (Completed) AT (Completed) BE (Completed) NL (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2019-001882-34 Sponsor Protocol Number: C-935788-058 Start Date*: 2020-01-28
    Sponsor Name:Rigel Pharmaceuticals, Inc.
    Full Title: A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
    Medical condition: Warm antibody autoimmune hemolytic anemia (wAIHA)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10003825 Autoimmune hemolytic anemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) DE (Prematurely Ended) AT (Prematurely Ended) DK (Completed) FR (Completed) HU (Prematurely Ended) BE (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-003564-37 Sponsor Protocol Number: PRN1008-005 Start Date*: 2016-04-21
    Sponsor Name:Principia Biopharma Australia Pty Ltd
    Full Title: An Open-Label, Phase 2, Pilot Study Investigating the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Oral Treatment with the BTK Inhibitor PRN1008 in Patients with Newly Diagn...
    Medical condition: Pemphigus: Pemphigus Vulgaris
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004858 10052802 Pemphigus vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2014-005000-19 Sponsor Protocol Number: CNTO1275SLE2001 Start Date*: 2015-03-18
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    18.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003201-34 Sponsor Protocol Number: U2970g Start Date*: 2016-08-07
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With ISN/RPS Class III or IV Lupus Nephritis
    Medical condition: ISN/RPS 2003 Class III or IV Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 23:03:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA